After a Decade of Research, Jowin Launches Revolutionary ORT Therapy to the World

Interview with the Chairman of Jowin – Q&A

Q1. What is Jowin, and what kind of therapy has the company developed?

A1. Jowin is a biomedical company headquartered in Seoul, South Korea, that has dedicated over 10 years to research and development to improve the survival chances of patients with terminal and refractory cancers.

We have developed an innovative cancer treatment called ORT Therapy (Oncothermia Resonance Therapy), offering a completely new approach compared to conventional cancer treatments.

Q2. What is ORT Therapy and how does it work?

A2. ORT Therapy involves the intake of a mineral-based herbal medicine called Micacine, followed by high-frequency hyperthermia stimulation to activate mineral particles accumulated in the body. This selectively destroys cancer cells.

Micacine alters the tumor microenvironment and disrupts the energy metabolism of cancer cells, inducing apoptosis (programmed cell death) and inhibiting proliferation.

The high-frequency device selectively targets cancer cells without affecting healthy cells, concentrating heat on tumors and maximizing anticancer effects — all without the severe side effects seen in chemotherapy or radiation therapy.

Q3. How has the mechanism of ORT Therapy been scientifically validated?

A3. Over the past decade, Jowin has collaborated with leading national medical school research teams, oncologists, traditional medicine doctors, and PhDs to investigate the mechanism behind ORT Therapy.

Research has revealed that Micacine disrupts cancer cell survival and proliferation pathways and induces apoptosis. These findings have been published in SCI-level international medical journals, providing strong scientific validation for ORT Therapy.

Q4. What clinical experiences have you had during the development of this therapy?

A4. Throughout the development of ORT Therapy, Jowin has conducted extensive observational studies in collaboration with cancer-specialized hospitals and oriental medicine clinics in Korea.

Through these studies, we observed improvements such as increased survival rates, tumor reduction, and enhanced quality of life (QOL) among patients with various types and stages of cancer. These experiences helped us continuously refine ORT Therapy for greater safety and effectiveness.

Q5. How does ORT Therapy differ from conventional cancer treatments?

A5. Traditional cancer treatments often destroy healthy cells along with cancerous ones, causing severe side effects.

In contrast, ORT Therapy selectively targets only cancer cells, resulting in significantly fewer side effects while also aiding immune system recovery and improving overall health.

It can also be used alongside conventional treatments, offering patients a broader range of therapeutic options.

Q6. Please tell us about the new “Refund Guarantee Program” you are launching overseas.

A6. Confident in the effectiveness of our treatment, we are offering a special guarantee: For our $500,000 one-year ORT Therapy program, if a terminal cancer patient does not survive for a year, or if a refractory cancer patient shows no meaningful improvement, the full treatment cost will be refunded.

This program aims to ease the financial burden on patients and families and encourage them to pursue treatment with confidence.

Q7. Can you share some specific treatment results?

A7. In Korea, among terminal cancer patients treated with ORT Therapy, over 50% survived beyond one year, and survival rates continue to improve over time.

We have also consistently observed meaningful outcomes such as tumor reduction, metastasis suppression, and significant improvements in quality of life, even among patients with metastatic or multiple cancers.

Q8. Who is the ideal candidate for ORT Therapy?

A8. Terminal cancer patients with no remaining standard treatment options, Patients with metastatic or multiple refractory cancers, Elderly patients or those with underlying health conditions who cannot tolerate chemotherapy, Patients seeking alternative treatment options

We provide personalized consultations to assess suitability and create individualized treatment plans. 

Q9. What are Jowin’s future plans?

A9. Jowin aims to provide new survival opportunities to terminal and refractory cancer patients worldwide through ORT Therapy.

We are preparing for international expansion by collaborating with global medical institutions and national cancer centers.

In addition, we continue investing in research and development to deliver hope to even more patients.

We have already established Jowin Asia in the Philippines and Jowin Global in Singapore.

Q10. ORT Therapy has recently attracted attention for combining a mineral-based herbal medicine with a high-frequency hyperthermia device called “CanSal(Hyper Thermia device).” What makes this therapy unique?

A10. Yes, ORT Therapy fundamentally differs from conventional cancer treatments.

Its key feature is the intake of Micacine (processed muscovite mineral medicine) followed by the use of a personal high-frequency hyperthermia device called CanSal.

Micacine targets heat shock proteins (HSPs) in cancer cells, and CanSal precisely heats the tumor, selectively eliminating cancer cells.

This is the first approach of its kind globally, maximizing the body’s natural healing power without causing harmful side effects.

Q11. How is CanSal different from conventional hyperthermia devices?

A11. There are three key innovations:

First, affordability — whereas conventional hospital hyperthermia equipment costs hundreds of thousands of dollars, CanSal is available at one-tenth the cost, greatly reducing patient burden.

Second, portability — CanSal is compact and allows patients to continue treatment conveniently at home without hospital visits.

Third, precision — Micacine enhances the targeting accuracy. After Micacine intake, cancer cells selectively absorb minerals within 3–4 hours, and CanSal focuses heat precisely on these cells, destroying cancer tissue while protecting healthy tissue.

Q12. Is it safe for patients to treat themselves at home?

A12. CanSal is equipped with an automatic temperature control system that prevents overheating and maintains the optimal therapeutic temperature of 42–43°C, ensuring safe and effective use.

Years of clinical application in Korea have demonstrated its safety without the side effects typically seen in traditional treatments.

Today, many terminal and refractory cancer patients in Korea are safely and effectively using it at home.

Jowin’s mission is to make cancer treatment accessible and affordable worldwide, replacing expensive hospital therapies with Micacine and CanSal to alleviate financial and physical suffering for underprivileged patients.

We will continue to advance the fusion of herbal science and cutting-edge technology to accelerate the conquest of cancer.

Q13. Lastly, is there a message you would like to share with patients and their families?

A13. Being diagnosed with terminal cancer does not mean you have to give up.

Jowin’s 10+ years of research and dedication are not just theories — they are based on real experiences of saving patients’ lives.

We exist to save each and every patient.

Do not give up. Join us at Jowin in seeking new hope.

Source: http://www.wikileaks-kr.org/news/articleView.html?idxno=167522